Showing 281-290 of 333 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| bifunctional RNA therapeutics for T1D | University of Miami | Paolo Serafini | Cures | 01-February-2025 to 31-January-2028 | $900,000.00 |
| Enhance β-Cell Replacement Therapies via Localized Immune Modulation Using DIANA Nanocarriers | University of Miami | Peter Buchwald | Cures | 01-September-2023 to 31-August-2026 | $900,000.00 |
| Low-dose IL-2 and anti-CD40L as a therapy for type 1 diabetes | University of Miami | Thomas Malek | Cures | 01-June-2024 to 31-May-2027 | $927,000.00 |
| mIL-2/CD25 fusion protein and BTK inhibitor combination therapy for T1D | University of Miami | Wasif Khan | Cures | 01-May-2023 to 30-April-2026 | $974,996.00 |
| Injectable Glucose-Responsive Hydrogels for Multi-Hormone Therapy | University of Notre Dame | Matthew Webber | Improving Lives | 01-March-2020 to 28-February-2026 | $750,000.00 |
| Defining the Antigenic Landscape of Islet-Infiltrating T cells in Type 1 Diabetes | University of Pittsburgh | Alok Joglekar | Cures | 01-March-2023 to 28-February-2026 | $900,000.00 |
| Dock2-mediated T cell migration as a targetable shared mechanism in autoimmunity | University of Pittsburgh | Alok Joglekar | Cures | 01-September-2025 to 31-August-2026 | $149,999.05 |
| MRI of Pancreas Perfusion in Response to Glucose | University of Texas at Austin | Jack Virostko | Cures | 01-July-2023 to 30-June-2025 | $187,620.00 |
| Can Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Mitigate Diabetic Ketoacidosis Risk? | University of Texas Health Science Center at San Antonio | Muhammad Abdul-Ghani | Improving Lives | 01-June-2019 to 30-September-2025 | $1,573,835.31 |
| Structural approaches to understand biased insulin signaling and design glucose-binding proteins for smart insulin therapeutics | University of Utah | Amber Vogel | Improving Lives | 01-March-2024 to 28-February-2027 | $228,995.00 |